deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04869943

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer (ARTEST)

Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor

Sponsor: Veru Inc.

Conditions Metastatic Breast Cancer
Interventions Enobosarm Exemestane
Updated 24 times since 2021 Last updated: Jan 24, 2024 Started: Oct 12, 2021 Primary completion: Jan 9, 2024 Completion: Jan 9, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision

Other terminated trials from Veru Inc.

More terminations from Veru Inc.

Other Metastatic Breast Cancer trials with similar outcome

Browse all Metastatic Breast Cancer trials

A PHASE3 clinical study on Metastatic Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Veru Inc. and has accumulated 24 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Oct 2023 · 5 months · monthly snapshot~Oct 2023 – ~Feb 2024 · 4 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Feb 2024 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Active Not Recruiting → Terminated

  5. Oct 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

▶ Show 19 earlier versions

  1. May 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  4. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  5. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  6. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  7. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  8. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  9. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  10. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  11. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  12. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  13. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  14. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  15. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  16. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  17. Oct 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE3

  18. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE3

  19. Jun 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Veru Inc.
Data source: Veru Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Athens, United States , Barcelona, Spain , Boston, United States , Chandler, United States , Cincinnati, United States , Clearwater, United States , Dallas, United States , Denver, United States , Dnipro, Ukraine and 37 more locations